Glyconjugate Vaccines
US-2024382585-A1 · Nov 21, 2024 · US
US11065323B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11065323-B2 |
| Application number | US-200913126146-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 27, 2009 |
| Priority date | Oct 27, 2008 |
| Publication date | Jul 20, 2021 |
| Grant date | Jul 20, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A process for purifying a Streptococcus pyogenes GAS carbohydrate comprising a step of anionic exchange chromatography. The process provides a good yield of GAS carbohydrate. The saccharides of the invention have low levels of hyaluronic acid, protein and nucleic acid contamination.
Opening claim text (preview).
The invention claimed is: 1. A process for purifying group A streptococcus (GAS) carbohydrate, comprising: a first step of filtration or ultrafiltration of an aqueous suspension of GAS carbohydrate, polyrhamnose, and hyaluronic acid, wherein said aqueous suspension was prepared by reductive acid treatment of GAS bacteria such that the GAS carbohydrate, polyrhamnose and the hyaluronic acid were released from the GAS bacteria; a second step of anionic exchange chromatography on a mixture comprising the GAS carbohydrate, polyrhamnose and the hyaluronic acid from the first step, wherein the anionic exchange chromatography is performed under conditions that allow flow through of the GAS carbohydrate and less than 1% by weight of the hyaluronic acid, and a third step, which comprises tangential flow filtration using a 5 or 10 kDa cut-off membrane of a mixture comprising the GAS carbohydrate from the second step, wherein the process yields a purified GAS carbohydrate comprising a level of hyaluronic acid contamination that is: a) less than 80 ng/ml; or b) less than 1% by weight of the hyaluronic acid relative to the weight of the GAS carbohydrate; and a polyrhamnose impurity of less than 20% by weight of the polyrhamnose relative to the weight of the GAS carbohydrate. 2. The process of claim 1 , wherein the purified GAS carbohydrate has a molecular weight of about 10 kDa. 3. The process of claim 1 or claim 2 , wherein the GAS carbohydrate is partially or fully de-N-acetylated. 4. The process of claim 1 , wherein the first step is the filtration and the filtration is by orthogonal filtration using a 0.65 μm filter. 5. The process of claim 1 , wherein the first step is the ultrafiltration and the ultrafiltration is by tangential flow filtration using a 30 kDa cut-off membrane. 6. The process of claim 1 , wherein the anionic exchange chromatography step is carried out using a Q-resin as anionic exchange matrix. 7. The process of claim 1 , wherein the anionic exchange chromatography step is carried out using 1 mL of anionic exchange matrix resin for every 1 mg of GAS carbohydrate. 8. The process of claim 1 , wherein a mobile phase buffer for the anionic exchange chromatography comprises alcohol. 9. The process of claim 8 , wherein the final alcohol concentration in the mobile phase buffer is between 15% and 25%. 10. The process of claim 8 or claim 9 , wherein the alcohol is ethanol. 11. The process of claim 1 , wherein the process comprises one or more gel filtration step(s) after the anionic exchange chromatography step. 12. The process of claim 11 , wherein the gel filtration step(s) are carried out using a dextran gel as gel filtration matrix. 13. The process of claim 11 or claim 12 , wherein the gel filtration step(s) are carried out using 1 mL of gel filtration matrix for every 0.2 mg of GAS carbohydrate. 14. The process of claim 11 , wherein the gel filtration step(s) are performed using a mobile phase buffer, which is the same as a mobile phase buffer used in the anionic exchange chromatography step. 15. The process of claim 11 , wherein the gel filtration step(s) are performed using a mobile phase buffer comprising alcohol at a concentration between 15% and 25%. 16. The process of claim 1 , wherein the process comprises one or more steps of concentrating the GAS carbohydrate after the anionic exchange chromatography step. 17. The process of claim 1 , wherein the process includes a further step of conjugating the purified GAS carbohydrate to a carrier molecule. 18. The process of claim 1 , further comprising formulating the purified GAS carbohydrate into a pharmaceutical composition. 19. The process of claim 1 , wherein the anionic exchange chromatography step is carried out using a DEAE resin as anionic exchange matrix. 20. The process of claim 1 , wherein the third step comprises tangential flow filtration using the 5 kDa cut-off membrane. 21. The process of claim 1 , wherein the polyrhamnose impurity is less than 4.5% by the weight of the polyrhamnose relative to the weight of the GAS carbohydrate.
Streptococcus · CPC title
Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation · CPC title
Ultrafiltration · CPC title
Anion-exchange · CPC title
Inorganic adjuvants · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.